Literature DB >> 23959290

Metabolomic identification of diagnostic plasma biomarkers in humans with chronic heart failure.

Juan Wang1, Zhongfeng Li, Jianxin Chen, Huihui Zhao, Liangtao Luo, Chan Chen, Xuegong Xu, Wenting Zhang, Kuo Gao, Bin Li, Junpeng Zhang, Wei Wang.   

Abstract

Chronic heart failure (CHF), as a progressive clinical syndrome, is characterized by failure of enough blood supply from the heart to meet the body's metabolic demands, and there is intense interest in identifying novel biomarkers that could make contributions to the diagnosis of CHF. Metabolomics, compared with current diagnostic approaches, could investigate many metabolic perturbations within biological systems. The overarching goal of the work discussed here is to apply a high-throughput approach to identify metabolic signatures and plasma diagnostic biomarkers underlying CHF by 1H-NMR spectroscopy. Plasma samples from 39 patients with CHF and 15 controls were analyzed by NMR spectroscopy. After processing the data, orthogonal partial least square discriminant analysis (OPLS-DA) was performed. The statistical model revealed good explained variance and predictability, and the diagnostic performance assessed by leave-one-out analysis exhibited 92.31% sensitivity and 86.67% specificity. The OPLS-DA score plots of spectra revealed good separation between case and control on the level of metabolites, and multiple biochemical changes indicated hyperlipidemia, alteration of energy metabolism and other potential biological mechanisms underlying CHF. It was concluded that the NMR-based metabolomics approach demonstrated good performance to identify diagnostic plasma markers and provided new insights into metabolic process related to CHF.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23959290     DOI: 10.1039/c3mb70227h

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  35 in total

1.  Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure.

Authors:  Juntuo Zhou; Xi Chen; Wei Chen; Lijun Zhong; Ming Cui
Journal:  Mol Cell Biochem       Date:  2021-05-11       Impact factor: 3.396

2.  Metabolomic analysis of serum and myocardium in compensated heart failure after myocardial infarction.

Authors:  M Dan McKirnan; Yasuhiro Ichikawa; Zheng Zhang; Alice E Zemljic-Harpf; Sili Fan; Dinesh Kumar Barupal; Hemal H Patel; H Kirk Hammond; David M Roth
Journal:  Life Sci       Date:  2019-02-05       Impact factor: 5.037

3.  Critical review of reporting of the data analysis step in metabolomics.

Authors:  E C Considine; G Thomas; A L Boulesteix; A S Khashan; L C Kenny
Journal:  Metabolomics       Date:  2017-12-01       Impact factor: 4.290

Review 4.  Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Authors:  Bassant Orabi; Rasha Kaddoura; Amr S Omar; Cornelia Carr; Abdulaziz Alkhulaifi
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 5.  The Modulating Effects of Cardiac Resynchronization Therapy on Myocardial Metabolism in Heart Failure.

Authors:  Yi-Zhou Xu; Chao-Feng Chen; Bin Chen; Xiao-Fei Gao; Wei Hua; Yong-Mei Cha; Petras P Dzeja
Journal:  Pacing Clin Electrophysiol       Date:  2016-12-07       Impact factor: 1.976

6.  Cardiac resynchronization therapy induces adaptive metabolic transitions in the metabolomic profile of heart failure.

Authors:  Emirhan Nemutlu; Song Zhang; Yi-Zhou Xu; Andre Terzic; Li Zhong; Petras D Dzeja; Yong-Mei Cha
Journal:  J Card Fail       Date:  2015-04-22       Impact factor: 5.712

7.  Serum amine-based metabolites and their association with outcomes in primary prevention implantable cardioverter-defibrillator patients.

Authors:  Yiyi Zhang; Elena Blasco-Colmenares; Amy C Harms; Barry London; Indrani Halder; Madhurmeet Singh; Samuel C Dudley; Rebecca Gutmann; Eliseo Guallar; Thomas Hankemeier; Gordon F Tomaselli; Alan Cheng
Journal:  Europace       Date:  2015-10-25       Impact factor: 5.214

Review 8.  Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling.

Authors:  Wynn G Hunter; Jacob P Kelly; Robert W McGarrah; William E Kraus; Svati H Shah
Journal:  Curr Heart Fail Rep       Date:  2016-06

9.  Metabolomic fingerprint of heart failure with preserved ejection fraction.

Authors:  Beshay N Zordoky; Miranda M Sung; Justin Ezekowitz; Rupasri Mandal; Beomsoo Han; Trent C Bjorndahl; Souhaila Bouatra; Todd Anderson; Gavin Y Oudit; David S Wishart; Jason R B Dyck
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

10.  Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial.

Authors:  Nerea Becerra-Tomás; Miguel Ruiz-Canela; Pablo Hernández-Alonso; Mònica Bulló; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary B Clish; Ramon Estruch; Emilio Ros; Montserrat Fitó; Chih-Hao Lee; Kerry Pierce; Fernando Arós; Lluís Serra-Majem; Liming Liang; Cristina Razquin; Enrique Gómez-Gracia; Miguel A Martínez-González; Frank B Hu; Dolores Corella; Jordi Salas-Salvadó
Journal:  Metabolites       Date:  2021-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.